Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.75M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.65M
Average 1.31M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +4.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +4.4% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Avalo Therapeutics, Inc. NASDAQ:AVTX | $448.71M | $7.76 | Not rated | -3.6 | -60.39% |
Fennec Pharmaceuticals Inc. NASDAQ:FENC | $407.48M | $11.62 | Not rated | -36.3 | +55.20% |
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $320.09M | $10.99 | Not rated | -4.3 | -29.69% |
Immuneering Corporation NASDAQ:IMRX | $240.27M | $3.71 | Not rated | -3.6 | -51.61% |
Inventiva S.A. NASDAQ:IVA | $191.29M | $3.68 | Not rated | -5.5 | -22.97% |
Abeona Therapeutics Inc. NASDAQ:ABEO | $138.30M | $2.42 | Not rated | 4.9 | -41.96% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.55% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $79.59M | $0.35 | Not rated | -1.3 | -74.78% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -73.83% |
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | $29.11M | $1.33 | Not rated | -1.2 | -59.86% |
Continue the stock analysis
Jump to another research area for this company.